false 0001739104 0001739104 2024-10-16 2024-10-16 0001739104 us-gaap:CommonStockMember 2024-10-16 2024-10-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): October 16, 2024

 

Elanco Animal Health Incorporated

(Exact name of registrant as specified in its charter)

 

Indiana  001-38661  82-5497352

(State or other jurisdiction
of incorporation)

  (Commission
File Number)		 

(I.R.S. Employer

Identification No.)

 

2500 Innovation Way

Greenfield, Indiana

(Address of principal executive offices)

 

46140

(Zip Code)

 

Registrant’s telephone number, including area code: (877) 352-6261

 

Not Applicable

(Former Name or Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on which
registered

Common stock, no par value   ELAN   New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

¨  Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 7.01 Regulation FD Disclosure

 

On October 15, 2024, representatives of Elanco Animal Health Incorporated (the “Company”) presented the abstract titled “Serologic response to core booster vaccinations in dogs treated with a novel JAK inhibitor” at the International Society for Companion Animal Infectious Diseases (ISCAID) symposium.

 

The Zenrelia™ (ilunocitinib tablets) study summarized in the abstract was conducted by the Company with sixty-eight approximately 10-month-old Beagle dogs previously vaccinated more than seven months prior to receiving a booster vaccination. The dogs were randomly assigned to three treatment groups stratified by sex and pre-study titer levels: sham dosed (control group) and ilunocitinib at 1X or 3X the label dose. The study concluded that when dogs were administered ilunocitinib for 56 days at 1X or 3X the labeled dose, the number of dogs with protective titers on days 43 and 56 following administration of canine core booster vaccinations, including rabies, were similar among all treated and control groups. No serious adverse events were observed.

 

A copy of the abstract has been posted on the Company’s Investors Relations website under the “Zenrelia Approval Call” event.

 

Additionally, the Company has received approval for Zenrelia™ in Canada. Further information is available via the Health Canada Drug Product Database website.

 

The information in this Item 7.01 is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Elanco Animal Health Incorporated
   
Date: October 16, 2024 By: /s/ Todd Young
    Name:  Todd Young
    Title:  Executive Vice President and Chief Financial Officer

 

 

 

v3.24.3
Cover
Oct. 16, 2024
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 16, 2024
Entity File Number 001-38661
Entity Registrant Name Elanco Animal Health Incorporated
Entity Central Index Key 0001739104
Entity Tax Identification Number 82-5497352
Entity Incorporation, State or Country Code IN
Entity Address, Address Line One 2500 Innovation Way
Entity Address, City or Town Greenfield
Entity Address, State or Province IN
Entity Address, Postal Zip Code 46140
City Area Code 877
Local Phone Number 352-6261
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common stock, no par value
Trading Symbol ELAN
Security Exchange Name NYSE
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Oct 2024 to Oct 2024 Click Here for more Elanco Animal Health Charts.
Elanco Animal Health (NYSE:ELAN)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Elanco Animal Health Charts.